SCHEMBL24590137

SCHEMBL24590137

CC(C)Nc1ccc(N2CC(C)OC(C)C2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.46
▸ TLR9 Q9NR96 1/20 0.41
▸ TLR8 Q9NR97 1/20 0.41
▸ TLR7 Q9NYK1 1/20 0.41
▸ SMO Q99835 2/20 0.41
▸ PGR P06401 1/20 0.41
▸ GPR183 P32249 1/20 0.41
▸ BCL6 P41182 2/20 0.41
▸ MAPT P10636 1/20 0.40
▸ BTK Q06187 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.39
▸ SOS1 Q07889 3/20 0.38
▸ DYRK1A Q13627 2/20 0.38
▸ CLK2 P49760 1/20 0.38
▸ CLK3 P49761 1/20 0.38
▸ WNT1 P04628 1/20 0.38
▸ AOC3 Q16853 2/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ GAK O14976 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24590334 1.00 KMT2A (0.46) KMT2ATLR9TLR8TLR7SMO
SCHEMBL13105214 0.84 KMT2A (0.49) KMT2ATLR9TLR8TLR7SMO
SCHEMBL24590318 0.80 KMT2A (0.46) KMT2ATLR9TLR8TLR7SMO
SCHEMBL24590136 0.78 MAPT (0.51) KMT2AMAPT
SCHEMBL17108649 0.78 KMT2A (0.49) KMT2ATLR9TLR8TLR7MAPT
SCHEMBL276991 0.78 KMT2A (0.49) KMT2ATLR9TLR8TLR7MAPT
SCHEMBL20004006 0.77 KMT2A (0.51) KMT2ATLR9TLR8TLR7SMO
SCHEMBL23019809 0.77 KMT2A (0.51) KMT2ATLR9TLR8TLR7SMO
SCHEMBL13034793 0.77 MAPT (0.54) KMT2AMAPT
SCHEMBL84397 0.76 LRRK2 (0.43) TLR9TLR8TLR7BCL6BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME TPX2, AIMP2, CDYL2 KMT2A 1721/4885TLR9 2035/4885TLR8 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback